PURPOSE: Radiation Therapy Oncology Group 95-17 is a prospective Phase II cooperative group trial of accelerated partial breast irradiation (APBI) alone using multicatheter brachytherapy after lumpectomy in select early-stage breast cancers. Tumor control and survival outcomes are reported. METHODS AND MATERIALS: Eligibility criteria included Stage I/II breast carcinoma confirmed to be <3 cm, unifocal, invasive nonlobular histology with zero to three positive axillary nodes without extracapsular extension. APBI treatment was delivered with either low-dose-rate (LDR) (45 Gy in 3.5-5 days) or high-dose-rate (HDR) brachytherapy (34 Gy in 10 twice-daily fractions over 5 days). End points evaluated included in-breast control, regional control, mastectomy-free rate, mastectomy-free survival, disease-free survival, and overall survival. The study was designed to analyze the HDR and LDR groups separately and without comparison. RESULTS: Between 1997 and 2000, 100 patients were accrued and 99 were eligible; 66 treated with HDR brachytherapy and 33 treated with LDR brachytherapy. Eighty-seven patients had T1 lesions and 12 had T2 lesions. Seventy-nine were pathologically N0 and 20 were N1. Median follow-up in the HDR group is 6.14 years with the 5-year estimates of in-breast, regional, and contralateral failure rates of 3%, 5%, and 2%, respectively. The LDR group experienced similar results with a median follow-up of 6.22 years. The 5-year estimates of in-breast, regional, and contralateral failure rates of 6%, 0%, and 6%, respectively. CONCLUSION: Patients treated with multicatheter partial breast brachytherapy in this trial experienced excellent in-breast control rates and overall outcome that compare with reports from APBI studies with similar extended follow-up.
PURPOSE: Radiation Therapy Oncology Group 95-17 is a prospective Phase II cooperative group trial of accelerated partial breast irradiation (APBI) alone using multicatheter brachytherapy after lumpectomy in select early-stage breast cancers. Tumor control and survival outcomes are reported. METHODS AND MATERIALS: Eligibility criteria included Stage I/II breast carcinoma confirmed to be <3 cm, unifocal, invasive nonlobular histology with zero to three positive axillary nodes without extracapsular extension. APBI treatment was delivered with either low-dose-rate (LDR) (45 Gy in 3.5-5 days) or high-dose-rate (HDR) brachytherapy (34 Gy in 10 twice-daily fractions over 5 days). End points evaluated included in-breast control, regional control, mastectomy-free rate, mastectomy-free survival, disease-free survival, and overall survival. The study was designed to analyze the HDR and LDR groups separately and without comparison. RESULTS: Between 1997 and 2000, 100 patients were accrued and 99 were eligible; 66 treated with HDR brachytherapy and 33 treated with LDR brachytherapy. Eighty-seven patients had T1 lesions and 12 had T2 lesions. Seventy-nine were pathologically N0 and 20 were N1. Median follow-up in the HDR group is 6.14 years with the 5-year estimates of in-breast, regional, and contralateral failure rates of 3%, 5%, and 2%, respectively. The LDR group experienced similar results with a median follow-up of 6.22 years. The 5-year estimates of in-breast, regional, and contralateral failure rates of 6%, 0%, and 6%, respectively. CONCLUSION:Patients treated with multicatheter partial breast brachytherapy in this trial experienced excellent in-breast control rates and overall outcome that compare with reports from APBI studies with similar extended follow-up.
Authors: F A Vicini; L L Kestin; N S Goldstein; P Y Chen; J Pettinga; R C Frazier; A A Martinez Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Alphonse G Taghian; Kevin R Kozak; Karen P Doppke; Angela Katz; Barbara L Smith; Michele Gadd; Michelle Specht; Kevin Hughes; Kristina Braaten; Lisa A Kachnic; Abram Recht; Simon N Powell Journal: Int J Radiat Oncol Biol Phys Date: 2006-01-06 Impact factor: 7.038
Authors: Robert R Kuske; Kathryn Winter; Douglas W Arthur; John Bolton; Rachel Rabinovitch; Julia White; William Hanson; R M Wilenzick Journal: Int J Radiat Oncol Biol Phys Date: 2006-02-28 Impact factor: 7.038
Authors: Frank A Vicini; J Vito Antonucci; Michelle Wallace; Samuel Gilbert; Neal S Goldstein; Larry Kestin; Peter Chen; Jonathan Kunzman; Thomas Boike; Pamela Benitez; Alvaro Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-15 Impact factor: 7.038
Authors: Timothy Whelan; Robert MacKenzie; Jim Julian; Mark Levine; Wendy Shelley; Laval Grimard; Barbara Lada; Himu Lukka; Francisco Perera; Anthony Fyles; Ethan Laukkanen; Sunil Gulavita; Veronique Benk; Barbara Szechtman Journal: J Natl Cancer Inst Date: 2002-08-07 Impact factor: 13.506
Authors: Martin Keisch; Frank Vicini; Robert R Kuske; Mary Hebert; Julia White; Coral Quiet; Doug Arthur; Troy Scroggins; Oscar Streeter Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Julia White; Kathryn Winter; Robert R Kuske; John S Bolton; Douglas W Arthur; Troy Scroggins; Rachel A Rabinovitch; Tracy Kelly; Leonard M Toonkel; Frank A Vicini; Beryl McCormick Journal: Int J Radiat Oncol Biol Phys Date: 2016-04-02 Impact factor: 7.038